SR One Capital Management LP Has $80.16 Million Position in Mineralys Therapeutics, Inc. $MLYS

SR One Capital Management LP decreased its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 32.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,113,933 shares of the company’s stock after selling 1,014,000 shares during the period. Mineralys Therapeutics accounts for approximately 11.6% of SR One Capital Management LP’s holdings, making the stock its 4th biggest holding. SR One Capital Management LP owned 3.19% of Mineralys Therapeutics worth $80,160,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of Mineralys Therapeutics by 354.4% during the 3rd quarter. Barclays PLC now owns 653,830 shares of the company’s stock worth $24,793,000 after purchasing an additional 509,946 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Mineralys Therapeutics in the 3rd quarter worth approximately $216,000. American Century Companies Inc. increased its holdings in Mineralys Therapeutics by 5.4% during the third quarter. American Century Companies Inc. now owns 879,682 shares of the company’s stock valued at $33,358,000 after buying an additional 44,901 shares during the period. Greenland Capital Management LP increased its holdings in Mineralys Therapeutics by 958.5% during the third quarter. Greenland Capital Management LP now owns 105,853 shares of the company’s stock valued at $4,014,000 after buying an additional 95,853 shares during the period. Finally, Citigroup Inc. raised its stake in Mineralys Therapeutics by 501.7% in the third quarter. Citigroup Inc. now owns 163,168 shares of the company’s stock worth $6,187,000 after buying an additional 136,050 shares in the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 192,715 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30. Following the completion of the transaction, the insider directly owned 61,804 shares of the company’s stock, valued at approximately $2,164,376.08. This trade represents a 75.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jon Congleton sold 16,236 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $32.62, for a total transaction of $529,618.32. Following the completion of the sale, the chief executive officer directly owned 639,151 shares in the company, valued at $20,849,105.62. This trade represents a 2.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 340,748 shares of company stock worth $11,697,169. 25.56% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

MLYS has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Stifel Nicolaus raised their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. HC Wainwright boosted their target price on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Finally, Wells Fargo & Company raised their price target on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Mineralys Therapeutics Stock Down 7.1%

MLYS opened at $26.72 on Friday. Mineralys Therapeutics, Inc. has a 52-week low of $9.69 and a 52-week high of $47.65. The company has a market cap of $2.11 billion, a P/E ratio of -9.06 and a beta of 0.57. The firm’s 50-day moving average price is $31.54 and its 200-day moving average price is $34.85.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.